RT Journal Article
SR Electronic
T1 Cancer-associated thrombosis: the when, how and why
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 180119
DO 10.1183/16000617.0119-2018
VO 28
IS 151
A1 Caio J. Fernandes
A1 Luciana T. K. Morinaga
A1 José L. Alves,  Jr
A1 Marcela A. Castro
A1 Daniela Calderaro
A1 Carlos V. P. Jardim
A1 Rogerio Souza
YR 2019
UL http://err.ersjournals.com/content/28/151/180119.abstract
AB Cancer-associated thrombosis (CAT) is a condition in which relevance has been increasingly recognised both for physicians that deal with venous thromboembolism (VTE) and for oncologists. It is currently estimated that the annual incidence of VTE in patients with cancer is 0.5% compared to 0.1% in the general population. Active cancer accounts for 20% of the overall incidence of VTE. Of note, VTE is the second most prevalent cause of death in cancer, second only to the progression of the disease, and cancer is the most prevalent cause of deaths in VTE patients. Nevertheless, CAT presents several peculiarities that distinguish it from other VTE, both in pathophysiology mechanisms, risk factors and especially in treatment, which need to be considered. CAT data will be reviewed in this review.Cancer-associated thrombosis (CAT) presents peculiar features (risk factors and pathophysiology) that distinguish it from common VTE cases. Treatment of CAT requires a different approach, since the patients are more prone to recurrence and bleeding. http://ow.ly/j1Lu30nYmd5